The immune checkpoint inhibitor durvalumab may have a role in the treatment of EGFR+ tumours with high PD-L1 expression, results from the phase 2 ATLANTIC study show. Published this week in Lancet Oncology the open-label, single-arm trial involved 444 patients with heavily pre-treated advanced non-small cell lung cancer (NSCLC) from 139 study centres in Asia, Europe, ...
Immunotherapy could have a role in advanced NSCLC: ATLANTIC.
By Nicola Garrett
13 Mar 2018